SecBot SecBot
Biotech Drug Report Generated Oct 26, 2026

RXC007

SKYE·Skye Bioscience, Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Phase 2a (completed)
Time to market
Unknown, Phase 2a completed, Phase 2b not yet initiated; a partnership-dependent path with no announced timeline
Why 2/10
No hard dated catalyst exists for RXC007 in the next ~12 months, Phase 2a has already reported, no Phase 2b start date has been set, and the drug is being positioned for partnering rather than internal advancement by the combined Fibrx entity.
Actionable Insight NEUTRAL

RXC007 has no scheduled binary catalyst; the key event to watch is the Skye-Redx merger closing (expected Q4 2026) and whether Fibrx announces a partnering deal for RXC007 afterwards. Any partnership terms (upfront, milestones) could serve as a partial valuation floor for this asset.

Price Chart

Loading chart...

Executive Summary

RXC007 (zelasudil) is a selective ROCK2 inhibitor that has completed a Phase 2a signal-searching study in idiopathic pulmonary fibrosis (IPF), showing a well-tolerated safety profile and encouraging early efficacy signals including a numerical reduction in FVC decline. Originally developed by private UK biotech Redx Pharma, the asset is being acquired by Skye Bioscience (SKYE) via a reverse-merger announced August 14, 2026, that will form a new Nasdaq-listed entity called Fibrx Therapeutics. However, RXC007 is not the combined company's lead asset, that distinction belongs to RXC008 (for fibrostenotic Crohn's disease). RXC007 is explicitly positioned for out-licensing/partnering, and no Phase 2b trial start date or specific development timeline has been announced. The drug currently lacks a near-term binary catalyst, and its value to SKYE/Fibrx shareholders depends on securing a partnership deal.

How It Works

RXC007 (zelasudil) is a small-molecule pill that selectively inhibits ROCK2, an enzyme involved in promoting fibrosis (scar tissue formation). By blocking ROCK2, the drug aims to reduce the excessive scarring that damages organs in diseases like idiopathic pulmonary fibrosis (IPF), a progressive lung disease where the lungs become stiff and scarred.

Trial Status

Phase 2a signal-searching study in IPF completed H1 2025 with results presented at ERS September 2025 (NCT05570058). The trial showed the drug was well-tolerated with early anti-fibrotic activity signals. A Phase 2b has been discussed as a future step but not initiated or publicly dated. RXC007 is being positioned by Fibrx Therapeutics for partnering rather than internal advancement.

The Two-Sided Case

▲ Bull Case4
RXC007 (zelasudil) is a highly selective ROCK2 inhibitor that showed encouraging Phase 2a data in IPF: well-tolerated with a numerical 47% reduction in FVC decline at the 20mg BID dose and evidence of anti-fibrotic activity sustained through 24 weeks in an open-label extension.
The combined Fibrx entity is well-capitalized ($125M in committed financing, projected to fund operations into 2029), providing runway to advance or partner RXC007 without near-term financing risk.
RXC007 has potential in multiple large fibrotic indications beyond IPF, including cancer-associated fibrosis and MASH, expanding its total addressable market if successfully developed.
Baker Bros. Advisors held a $1.09M position (1.58M shares) as of Q2 2026, representing a high-conviction institutional holder in the biotech space.
▼ Bear Case4
RXC007 is a secondary asset in the combined Fibrx pipeline, the lead program is RXC008 for fibrostenotic Crohn's, and RXC007 is explicitly positioned for out-licensing/partnering, meaning the company does not plan to bear full development cost or capture all upside.
The Phase 2a data, while positive, showed only numerical (not statistically significant) reduction in FVC decline, a 'signal searching' study that needs confirmation in a larger Phase 2b trial, which has not been initiated or dated.
Pre-transaction Skye shareholders were diluted to ~5.38% of the combined entity per the Aug 14, 2026 transaction terms; massive insider selling in Sept 2026 by 10% owners (5AM Partners, Andrew Schwab) at ~$1.61/share suggests insiders are exiting post-merger.
SKYE stock has collapsed from a 52-week high of $13.28 to ~$1.57, reflecting the extreme dilutive nature of the reverse-merger transaction.

Upcoming Catalysts

  • Skye-Redx merger closing expected Q4 2026 (corporate event, not drug-specific)
  • Potential partnership/out-licensing announcement for RXC007, no timeline

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Skye Bioscience, Inc. PREM14A SKYE ·Originating report

Sources · 10

Hover a chip for the title
1 redxpharma.com2 ir.skyebioscience.com3 clinicaltrials.gov4 firstwordpharma.com5 fiercebiotech.com6 sec.gov7 sec.gov8 publications.ersnet.org9 panabee.com10 trialradar.com